Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers.
OBJECTIVE
To evaluate prophylactic salpingo-oophorectomy uptake and timing among BRCA1/2 mutation carriers in a cancer risk assessment program.


METHODS
Clinical records of female BRCA1/2 mutation carriers who received cancer genetic counseling between 1996 and 2003 were reviewed to determine the completion and the timing of prophylactic salpingo-oophorectomy. Logistic regression models evaluated associations between subject characteristics and surgery. Survival analysis methods were used to estimate the distribution of time to surgery.


RESULTS
Among 88 women, 70% underwent prophylactic salpingo-oophorectomy. Prophylactic salpingo-oophorectomy was associated with older age, white race, having children, and a family history of ovarian cancer. Many women waited more than 12 months to undergo surgery and some delayed by several years. Younger age and not having children were associated with delays to surgery.


CONCLUSIONS
Prophylactic salpingo-ooporectomy is an acceptable risk reduction measure for many BRCA1/2 mutation carriers. Some women make this decision many years after genetic testing. Continued discussion of the risks and benefits of risk reduction options may facilitate the uptake of recommended risk reduction interventions among BRCA mutation carriers.
Bradbury
Angela R
AR
University of Chicago Center for Clinical Cancer Genetics, Chicago, Illinois.|Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, Illinois.
Ibe
Comfort N
CN
University of Chicago Center for Clinical Cancer Genetics, Chicago, Illinois.|Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, Illinois.
Dignam
James J
JJ
Department of Health Studies, University of Chicago, Chicago, Illinois.
Cummings
Shelly A
SA
University of Chicago Center for Clinical Cancer Genetics, Chicago, Illinois.|Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, Illinois.
Verp
Marion
M
University of Chicago Center for Clinical Cancer Genetics, Chicago, Illinois.|Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois.
White
Melody A
MA
University of Chicago Center for Clinical Cancer Genetics, Chicago, Illinois.|Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, Illinois.
Artioli
Grazia
G
Instituto Oncologico Veneto, Padove, Italy.
Dudlicek
Laura
L
University of Chicago Center for Clinical Cancer Genetics, Chicago, Illinois.|Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, Illinois.
Olopade
Olufunmilayo I
OI
University of Chicago Center for Clinical Cancer Genetics, Chicago, Illinois.|Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, Illinois.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics; D005187:Fallopian Tubes / Q000601:surgery*; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006580:Genetic Carrier Screening; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D010051:Ovarian Neoplasms / Q000235:genetics; D010052:Ovariectomy / Q000379:methods*; D040242:Risk Reduction Behavior